Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
NewLimit seeks a Scientist to design, formulate and characterize targeted LNPs with antibody conjugates, Nanobodies, and scFv’s to enable extra-hepatic delivery. This hands-on bench role collaborates with Delivery Sciences and biology teams to build the targeting LNP platform for diverse pipeline programs.
The role requires a PhD or MS with significant tLNP design experience, plus expertise in conjugation chemistry, purification, and analytical methods like LC and SPR.
NewLimit is a biotechnology company working to radically extend human healthspan. We're developing medicines to treat aging by reprogramming the epigenome, a new therapeutic mechanism to restore youthful function in aged cells. We've built the world's leading experimental and artificial intelligence system to discover reprogramming medicines at massive scale. Our first products are focused on restoring youthful metabolic, endothelial, and immune function.
NewLimit is seeking a Scientist to design, formulate and characterize targeted LNPs (tLNPs) with antibody conjugates, Nanobodies, and scFv's to build our targeting LNP platform with a particular focus on getting nucleic acid payloads into target cells and tissues beyond the liver.
This is a hands-on bench role with targeting compositional and reaction design ownership. You will work closely with the Delivery Sciences and biology teams to design and build relevant targeting lipids portfolio for NewLimit's pipeline programs.
NewLimit provides generous benefits so our team can remain focused on our mission:
Salary Range: $130,000 to $171,000. Compensation for the role will depend on a number of factors, including a candidate's qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.